{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:43:23Z","timestamp":1790462603144,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.intimp.2020.107262","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T12:26:32Z","timestamp":1607171192000},"page":"107262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Convalescent plasma may be a possible treatment for COVID-19: A systematic review"],"prefix":"10.1016","volume":"91","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-5196","authenticated-orcid":false,"given":"Kun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.107262_b0005","unstructured":"World Health Organization, Coronavirus disease (COVID-19) Situation Report\u2013Weekly epidemiological update - 10 November 2020. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update---10-november-2020 (accessed 12 November 2020)."},{"issue":"27","key":"10.1016\/j.intimp.2020.107262_b0010","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1503\/cmaj.200642","article-title":"Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis","volume":"192","author":"Devasenapathy","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.intimp.2020.107262_b0015","unstructured":"National Institutes of Health (NIH), COVID-19 Treatment Guidelines. https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/ (accessed 5 November 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0020","unstructured":"The guardian, Covid vaccine tracker: when will a coronavirus vaccine be ready?. https:\/\/www.theguardian.com\/world\/ng-interactive\/2020\/oct\/29\/covid-vaccine-tracker-when-will-a-coronavirus-vaccine-be-ready (accessed 5 November 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0025","doi-asserted-by":"crossref","unstructured":"P. Horby, W.S. Lim, J. Emberson et al., Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report, medRxiv 2020:2020.06.22.20137273. doi: https:\/\/doi.org\/10.1101\/2020.06.22.20137273.","DOI":"10.1101\/2020.06.22.20137273"},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2020.107262_b0035","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir. Ther."},{"issue":"14","key":"10.1016\/j.intimp.2020.107262_b0040","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2020.107262_b0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.107262_b0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","article-title":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.intimp.2020.107262_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106455","article-title":"The possible of immunotherapy for COVID-19: A systematic review","volume":"83","author":"AminJafari","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.107262_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review","author":"Rajendran","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2020.107262_b0065","article-title":"Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis","author":"Sarkar","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2020.107262_b0070","doi-asserted-by":"crossref","unstructured":"V. Piechotta, K.L. Chai, S.J. Valk et al., Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst. Rev. 7(7) (2020) CD013600. doi: 10.1002\/14651858.CD013600.pub2. Update in: Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600.","DOI":"10.1002\/14651858.CD013600.pub2"},{"key":"10.1016\/j.intimp.2020.107262_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.intimp.2020.107262_b0080","unstructured":"Ying Wang, Kun Zhu, Pengfei Huo, Yiming Guo, Tingting Guo, Shengnan Bi, Qian Yu, The efficacy and safety of convalescent plasma for Coronavirus Disease 2019 (COVID-19): a systematic review. PROSPERO 2020 CRD42020193625 Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020193625."},{"issue":"366","key":"10.1016\/j.intimp.2020.107262_b0085","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"355","key":"10.1016\/j.intimp.2020.107262_b0090","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"12","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.intimp.2020.107262_b0095","first-page":"CD008205","article-title":"Hepatic late adverse effects after antineoplastic treatment for childhood cancer","volume":"4","author":"Mulder","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"150\u2013158","key":"10.1016\/j.intimp.2020.107262_b0100","article-title":"Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. The skills and experience of GRADE methodologists can be assessed with a simple tool","volume":"79","author":"Norris","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.intimp.2020.107262_b0105","doi-asserted-by":"crossref","unstructured":"A. Gharbharan, C.C.E. Jordans, C. GeurtsvanKessel et al., Convalescent Plasma for COVID-19. A randomized clinical trial, medRxiv. 2020.07.01.20139857; doi: https:\/\/doi.org\/10.1101\/2020.07.01.20139857.","DOI":"10.1101\/2020.07.01.20139857"},{"issue":"5","key":"10.1016\/j.intimp.2020.107262_b0110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2020.107262_b0115","article-title":"Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial","author":"Avendano-Sola","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2020.107262_b0120","article-title":"Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)","author":"Agarwal","year":"2020","journal-title":"medRxiv"},{"issue":"17","key":"10.1016\/j.intimp.2020.107262_b0125","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2020.107262_b0130","article-title":"Convalescent plasma treatment of severe COVID-19: A matched control study","author":"Liu","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.intimp.2020.107262_b0140","article-title":"Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study","author":"Donato","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2020.107262_b0145","article-title":"Convalescent plasma for patients with severe COVID-19: a matched cohort study","author":"Rogers","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2020.107262_b0150","article-title":"Effect of convalescent plasma on mortality in patients with COVID-19 Pneumonia","author":"Salazar","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2020.107262_b0155","article-title":"Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality","author":"Salazar","year":"2020","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.intimp.2020.107262_b0160","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.2020006964","article-title":"Use of convalescent plasma in hospitalized patients with COVID-19: case series","volume":"136","author":"Hegerova","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.107262_b0165","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study","volume":"15","author":"Abolghasemi","year":"2020","journal-title":"Transfus Apher Sci."},{"issue":"3","key":"10.1016\/j.intimp.2020.107262_b0170","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq","volume":"28","author":"Rasheed","year":"2020","journal-title":"Infez Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107262_b0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2020007079","article-title":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.107262_b0180","article-title":"Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience","author":"Joyner","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.intimp.2020.107262_b0185","article-title":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial","author":"Perotti","year":"2020","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.intimp.2020.107262_b0190","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.intimp.2020.107262_b0195","article-title":"Convalescent plasma as potential therapy for severe COVID-19 pneumonia","author":"Valentini","year":"2020","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.intimp.2020.107262_b0200","first-page":"159","article-title":"Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study","volume":"72","author":"Olivares-Gazca","year":"2020","journal-title":"Rev. Invest. Clin."},{"issue":"10","key":"10.1016\/j.intimp.2020.107262_b0205","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/infdis\/jiaa505","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019","volume":"222","author":"Bradfute","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107262_b0210","article-title":"Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","author":"Madariaga","year":"2020","journal-title":"J Intern Med."},{"issue":"8","key":"10.1016\/j.intimp.2020.107262_b0215","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma","volume":"190","author":"Salazar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2020.107262_b0220","doi-asserted-by":"crossref","unstructured":"M. Ye, D. Fu, Y. Ren et al., Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online ahead of print, 2020 Apr 15], J. Med. Virol. 2020;10.1002\/jmv.25882 (accessed 31 July 2020).","DOI":"10.1002\/jmv.25882"},{"issue":"16","key":"10.1016\/j.intimp.2020.107262_b0225","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with Covid-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0230","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2020.107262_b0235","doi-asserted-by":"crossref","unstructured":"J.Y. Ahn, Y. Sohn, S.H. Lee et al., Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea, J. Korean Med. Sci. 35(14) (2020) e149. 10.3346\/jkms.(2020).35.e149.","DOI":"10.3346\/jkms.2020.35.e149"},{"key":"10.1016\/j.intimp.2020.107262_b0240","doi-asserted-by":"crossref","unstructured":"Y. Kong, C. Cai, L. Ling et al., Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma [published online ahead of print, 2020 May 21], Transfus. Apher. Sci. (2020) 102820. doi: 10.1016\/j.transci.2020.102820 (accessed 31 July 2020).","DOI":"10.1016\/j.transci.2020.102820"},{"key":"10.1016\/j.intimp.2020.107262_b0245","doi-asserted-by":"crossref","unstructured":"J. Anderson, J. Schauer, S. Bryant, C.R. Graves, The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report [published online ahead of print, 2020 May 16], Case Rep. Women Health. 27 (2020) e00221. doi: 10.1016\/j.crwh.2020.e00221 (accessed 31 July 2020).","DOI":"10.1016\/j.crwh.2020.e00221"},{"key":"10.1016\/j.intimp.2020.107262_b0250","doi-asserted-by":"crossref","unstructured":"O.E. \u00c7\u0131nar, B. Say\u0131nalp, E. Alada\u011f Karakulak et al., Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis [published online ahead of print, 2020 May 29], Transfus. Apher. Sci. (2020)102821. doi: 10.1016\/j.transci.2020.102821 (accessed 31 July 2020).","DOI":"10.1016\/j.transci.2020.102821"},{"issue":"56","key":"10.1016\/j.intimp.2020.107262_b0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amsu.2020.06.018","article-title":"A severe refractory COVID-19 patient responding to convalescent plasma; A case series","volume":"24","author":"Abdullah","year":"2020","journal-title":"Ann. Med. Surg. (Lond.)"},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13287-020-01802-8","article-title":"A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report","volume":"11","author":"Peng","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2020.107262_b0265","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.radcr.2020.07.031","article-title":"Radiological and clinical improvement in a patient with COVID-19 pneumonia postconvalescent plasma transfusion: A case report","volume":"15","author":"Al Helali","year":"2020","journal-title":"Radiol. Case Rep."},{"issue":"7","key":"10.1016\/j.intimp.2020.107262_b0270","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4329\/wjr.v12.i7.137","article-title":"Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report","volume":"12","author":"Jafari","year":"2020","journal-title":"World J. Radiol."},{"issue":"26","key":"10.1016\/j.intimp.2020.107262_b0275","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e239","article-title":"Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles","volume":"35","author":"Im","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2020.107262_b0280","article-title":"First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia","volume":"1","author":"Figlerowicz","year":"2020","journal-title":"Transfus. Apher. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0285","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12985-020-01354-6","article-title":"Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report","volume":"17","author":"Xu","year":"2020","journal-title":"Virol J."},{"key":"10.1016\/j.intimp.2020.107262_b0290","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma","volume":"3","author":"Karata\u015f","year":"2020","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.intimp.2020.107262_b0295","article-title":"Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy","volume":"19","author":"Naeem","year":"2020","journal-title":"Transpl. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-020-00329-x","article-title":"The efficacy assessment of convalescent plasma therapy for COVID-19 patients:a multi-center case series","volume":"5","author":"Zeng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"36","key":"10.1016\/j.intimp.2020.107262_b0305","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021596","article-title":"Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.intimp.2020.107262_b0310","doi-asserted-by":"crossref","unstructured":"R. Shankar, N. Radhakrishnan, S. Dua et al., Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. Transfus Apher Sci. 2020 Sep 24:102956. doi: 10.1016\/j.transci.2020.102956. Epub ahead of print. PMID: 32994125.","DOI":"10.1016\/j.transci.2020.102956"},{"key":"10.1016\/j.intimp.2020.107262_b0315","article-title":"Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications","volume":"30","author":"Jiang","year":"2020","journal-title":"Clin. Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0320","first-page":"45","article-title":"Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma","volume":"7","author":"Zhang","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.intimp.2020.107262_b0325","article-title":"Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome","volume":"4","author":"Diorio","year":"2020","journal-title":"Pediatr Blood Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2020.107262_b0330","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2020.107262_b0335","doi-asserted-by":"crossref","unstructured":"Ng KT, Oong XY, Lim SH, et al., Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections, Clin. Infect. Dis. 67(2)(2018)261-268.","DOI":"10.1093\/cid\/ciy063"},{"issue":"10","key":"10.1016\/j.intimp.2020.107262_b0340","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2020.107262_b0345","doi-asserted-by":"crossref","unstructured":"Chen B, Xia R, Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns [published online ahead of print, 2020 Jun 9], Vox. Sang. (2020);10.1111\/vox.12968. doi:10.1111\/vox.12968.","DOI":"10.1111\/vox.12968"},{"issue":"5","key":"10.1016\/j.intimp.2020.107262_b0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: A systematic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"issue":"6288","key":"10.1016\/j.intimp.2020.107262_b0355","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2020.107262_b0360","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107262_b0365","doi-asserted-by":"crossref","unstructured":"Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A, Convalescent plasma transfusion for the treatment of COVID-19: Systematic review [published online ahead of print, 2020 May 1], J. Med. Virol. (2020).10.1002\/jmv.25961. doi:10.1002\/jmv.25961. (accessed 31 July 2020).","DOI":"10.1002\/jmv.25961"},{"key":"10.1016\/j.intimp.2020.107262_b0370","doi-asserted-by":"crossref","unstructured":"Cao B, Wang Y, Wen D, et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med.382(19)(2020)1787-1799. doi:10.1056\/NEJMoa2001282.","DOI":"10.1056\/NEJMc2008043"},{"issue":"3","key":"10.1016\/j.intimp.2020.107262_b0375","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: The reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"1","key":"10.1016\/j.intimp.2020.107262_b0380","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2020.107262_b0385","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2020.107262_b0390","unstructured":"World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. http:\/\/apps.who.int\/iris\/rest\/bitstreams\/604045\/retrieve (accessed 31 July 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0395","unstructured":"Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma, Content current as of: 04\/13\/2020. https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma (accessed 31 July 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0400","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and Treatment of COVID-19(trial 6th edition). http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202002\/8334a8326dd94d329df351d7da8aefc2.shtml (accessed 31 July 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0405","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and Treatment of COVID-19(trial 7th edition). http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202003\/46c9294a7dfe4cef80dc7f5912eb1989.shtml (accessed 31 July 2020)."},{"key":"10.1016\/j.intimp.2020.107262_b0410","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and Treatment of COVID-19(trial 8th edition). http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202008\/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml (accessed 5 November 2020)."},{"issue":"17","key":"10.1016\/j.intimp.2020.107262_b0415","first-page":"249","article-title":"Drug Use and Transfusion Safety of Blood Donors","volume":"4","author":"Jun","year":"2020","journal-title":"Chinese Pharmacovigilance."},{"issue":"8","key":"10.1016\/j.intimp.2020.107262_b0420","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1537-2995.2006.00909.x","article-title":"Does blood donor history accurately reflect the use of prescription medications? A comparison of donor history and serum toxicologic analysis","volume":"46","author":"Melanson","year":"2006","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.intimp.2020.107262_b0425","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/vox.12230","article-title":"Presence of medication taken by blood donors in plasma for transfusion","volume":"108","author":"Van Tilborgh-de Jong","year":"2015","journal-title":"Vox. Sang."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:27:00Z","timestamp":1761586020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920337292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":85,"alternative-id":["S1567576920337292"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107262","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convalescent plasma may be a possible treatment for COVID-19: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107262"}}